Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-blind, Placeb......

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is running a Phase 1/2 trial called “A......

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study “A Study to Evaluate ALN-4915 in Adult Healt......

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is preparing a Phase 2 trial called “H......

Using the TipRanks Highest P/E Ratio Stocks tool, we identified three companies with high price-to-earnings (P/E) ratios and more than 40% upside p......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcutis Biotherapeutics (ARQT), The Ensign Group (EN......

In a report released today, William Pickering from Bernstein reiterated a Buy rating on Alnylam Pharma, with a price target of $447.00. According t......

Raymond James analyst Tiago Fauth maintained a Hold rating on Alnylam Pharma today and set a price target of $377.00. Fauth covers the Healthcare s......

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Alnylam Pharma (ALNY) and The Ensign......

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics......